Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 8c

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.64), $0.08 better than the analyst estimate of ($0.72).

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Medtronic completes $550 million Scientia Vascular acquisition
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results